^
    Back
    Association details:
    Biomarker:STRBP-JAK2 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C4 – Case Studies
    Source:
    Front Oncol
    Title:

    Identification of STRBP as a Novel JAK2 Fusion Partner Gene in a Young Adult With Philadelphia Chromosome-Like B-Lymphoblastic Leukemia

    Published date:
    01/11/2021
    Excerpt:
    Ph-like ALL proved refractory to traditional induction chemotherapy combined with ruxolitinib...a novel STRBP-JAK2 gene fusion in a Ph-like ALL patient with a very aggressive disease course, which proved resistant to chemotherapy combined with ruxolitinib
    DOI:
    10.3389/fonc.2020.611467